Biosyent Inc (TSXV:RX)
C$ 11 -0.15 (-1.35%) Market Cap: 127.46 Mil Enterprise Value: 111.19 Mil PE Ratio: 18.36 PB Ratio: 3.60 GF Score: 96/100

Q3 2019 Biosyent Inc Earnings Call Transcript

Nov 20, 2019 / NTS GMT
Release Date Price: C$6.65 (+11.20%)
RenÃ;C. Goehrum
BioSyent Inc. - Chairman, CEO & President

© -

Hello. Welcome to the BioSyent Q3 2019 Results Presentation. My name is René Goehrum, and I'm the President and CEO of BioSyent Inc.

I'm going to start today's presentation with a look at our quarter sales and profitability. So in the period ended September 30, our revenue hit $6.22 million, that was up 18% versus year ago. So the thing to note here is that $1 million of revenue was generated from FeraMAX customers outside of Canada. So we had reported in the past that we had somewhat of a backlog because of issues around import permits by our customer -- our largest customer. And so that backlog was shipped and -- to the end of September. And so that was $1 million of revenue essentially piled into 1 quarter and obviously had a positive impact on the quarter sales, and that trickled down through to both EBITDA and NIAT EBITDA up 15% to just under $2 million for the quarter and net income after tax at $1.53 million, up 21% versus a year ago. So this quarter represented our 37th consecutive profitable quarter.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot